Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Background The frequency of obesity has risen dramatically in recent years but only few
safe and effective drugs are currently available. We assessed the effect of liraglutide on …

OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1
receptor agonist) to metformin were compared with addition of placebo or glimepiride to …

Background New treatments for type 2 diabetes mellitus are needed to retain insulin–
glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to …

Diabetes mellitus is associated with a considerably increased risk of premature
atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to …

Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …

Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone
4 mg/day (all n≥ 228) or placebo (n= 114) with glimepiride (2–4 mg/day) on glycaemic …

Aims/hypothesis The aim of the study was to compare the efficacy and safety of liraglutide in
type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly, B31Arg, B32Arg human …

Background Weight loss is often key in the management of obese or overweight patients
with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight …